€0.091
Your prediction
Financial data and news for Cytophage Technologies Ltd.
sharewise wants to provide you with the best news and tools for Cytophage Technologies Ltd., so we directly link to the best financial data sources.
Financials
News
Cytophage Reports Successful Results and Data from Second EU Pilot Study for AviPhage
WINNIPEG, September 23, 2025 – Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced positive results from its follow-up European pilot study of
Cytophage Announces Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES
WINNIPEG, October 17, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today
Cytophage Announces the Commercialization of OvaPhage in Canada Through W.L.T. Distributors Inc.
Winnipeg, Manitoba – October 16, 2025 – Cytophage Technologies Ltd. (“Cytophage” or the “Company”), a biotechnology company developing innovative bacteriophage solutions for animal and human
Cytophage Receives Federal Support for Entry into European Market through France Biomanufacturing Mission
WINNIPEG, September 29, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) announced its participation in the Canadian biomanufacturing mission held in
Cytophage Identifies Two New Patient Candidates for Phage Therapy for Prosthetic Joint Infections
WINNIPEG, September 11, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that two patients have been selected as candidates eligible to
Cytophage Secures Health Canada Validation for OvaPhage and PhageFend Products for use in Food Safety
- Cytophage receives Letters of No Objection (LONO) from Health Canada for two of its cutting-edge bacteriophage products
- Regulatory milestone accelerates Cytophage’s
Cytophage Technologies Reports Successful E. Coli Containment in EU Pilot Study for AviPhage
Follow-up Study Underway with Results Expected in Q3
WINNIPEG, July 28, 2025 - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced promising